Investing.com -- Cue Biopharma (NASDAQ:CUE) shares plunged 30% in after-hours trading Thursday after the clinical-stage biopharmaceutical company announced plans for an underwritten public offering of common stock and accompanying warrants.
The company, which develops therapeutics to modulate disease-specific T cells for autoimmune diseases, said it would offer shares of its common stock or pre-funded warrants to purchase common stock, along with accompanying warrants to purchase additional shares. Cue Biopharma also plans to grant underwriters a 30-day option to purchase up to an additional 15% of the shares and/or warrants offered in the public offering.
H.C. Wainwright & Co. is serving as the sole book-running manager for the proposed offering, with Newbridge Securities Corporation acting as co-manager.
The sharp decline in share price reflects typical market reaction to public offerings, which often lead to dilution of existing shareholders’ stakes. The company noted that the offering is subject to market conditions, with no guarantee regarding completion timing or final terms.
Cue Biopharma did not disclose the intended use of proceeds from the offering in its announcement. The company focuses on developing novel therapeutic biologics that selectively engage and modulate disease-specific T cells for treating autoimmune diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
























